WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Chicago PD star Tracy Spiridakos explains why she is leaving the long
Caring for Cranes Meticulously
Working on Farms in Africa Full of Challenges, Pleasure
Judge dismisses felony convictions of 5 retired military officers in US Navy bribery case
Volunteer Work Enriches Family's Happiness
Blue Sky Rescue Team Captain Saving Lives — with Love
Kaifeng: Ancient Capital of Eight Dynasties
Duran homers and steals home as Red Sox beat Rays 5
China clocks world's 2nd best time in men's 4x100m medley relay victory at Hangzhou Asiad
NASCAR star Kyle Larson is embracing his Indianapolis 500 debut, right down to milking a cow
Chinese Children's Books Impress Overseas Readers, Gain Increasing Popularity